



US009517024B2

(12) **United States Patent**
Kiani et al.

(10) **Patent No.:** **US 9,517,024 B2**
(45) **Date of Patent:** **Dec. 13, 2016**

(54) **OPTICAL-BASED PHYSIOLOGICAL MONITORING SYSTEM**

(71) Applicant: **MASIMO CORPORATION**, Irvine, CA (US)

(72) Inventors: **Massi Joe E. Kiani**, Laguna Niguel, CA (US); **Michael O'Reilly**, Cupertino, CA (US)

(73) Assignee: **MASIMO CORPORATION**, Irvine, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 78 days.

(21) Appl. No.: **14/479,083**

(22) Filed: **Sep. 5, 2014**

(65) **Prior Publication Data**

US 2014/0378784 A1 Dec. 25, 2014

Related U.S. Application Data

(63) Continuation of application No. 12/885,430, filed on Sep. 17, 2010, now abandoned.

(60) Provisional application No. 61/243,161, filed on Sep. 17, 2009.

(51) **Int. Cl.**
A61B 5/1455 (2006.01)
A61B 5/0402 (2006.01)
A61B 5/0476 (2006.01)
A61B 5/00 (2006.01)
A61B 5/0205 (2006.01)

(52) **U.S. Cl.**
CPC **A61B 5/1455** (2013.01); **A61B 5/0205** (2013.01); **A61B 5/0402** (2013.01); **A61B 5/0476** (2013.01); **A61B 5/4821** (2013.01)

(58) **Field of Classification Search**
CPC ... A61B 5/02055; A61B 5/024; A61B 5/1112; A61B 5/02125; A61B 5/0285
USPC 604/65-67, 503, 890.1, 323
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,421,122 A * 12/1983 Duffy A61B 5/0484 600/544
4,960,128 A 10/1990 Gordon et al.
4,964,408 A 10/1990 Hink et al.
5,041,187 A 8/1991 Hink et al.
5,069,213 A 12/1991 Polczynski
5,163,438 A 11/1992 Gordon et al.
5,286,252 A * 2/1994 Tuttle A61K 31/135 604/20
5,319,355 A 6/1994 Russek
(Continued)

OTHER PUBLICATIONS

Binnie, C. et al., *Clinical Neurophysiology*, vol. 2, 2003. Elsevier Science. p. 707-790.

(Continued)

Primary Examiner — Bhisma Mehta


Assistant Examiner — Matthew A Engel

(74) *Attorney, Agent, or Firm* — Knobbe, Martens, Olson & Bear LLP

(57) **ABSTRACT**

A non-invasive, optical-based physiological monitoring system is disclosed. In an embodiment, the non-invasive, optical-based physiological monitoring system comprises an emitter configured to emit light into a tissue site of a living patient; a detector configured to detect the emitted light after attenuation by the tissue site and output a sensor signal responsive to the detected light; and a processor configured to determine, based on the sensor signal, a first physiological parameter indicative of a level of pain of the patient.

8 Claims, 8 Drawing Sheets



(56)	References Cited	6,157,850 A *	12/2000	Diab	G06K 9/0051 600/323
	U.S. PATENT DOCUMENTS	6,165,005 A	12/2000	Mills et al.	
		6,184,521 B1	2/2001	Coffin, IV et al.	
		6,206,830 B1	3/2001	Diab et al.	
		6,229,856 B1	5/2001	Diab et al.	
		6,232,609 B1	5/2001	Snyder et al.	
		6,236,872 B1	5/2001	Diab et al.	
		6,241,683 B1	6/2001	Macklem et al.	
		6,253,097 B1	6/2001	Aronow et al.	
		6,256,523 B1	7/2001	Diab et al.	
		6,263,222 B1	7/2001	Diab et al.	
		6,278,522 B1	8/2001	Lepper, Jr. et al.	
		6,280,213 B1	8/2001	Tobler et al.	
		6,285,896 B1	9/2001	Tobler et al.	
		6,301,493 B1	10/2001	Marro et al.	
		6,317,627 B1	11/2001	Ennen et al.	
		6,321,100 B1	11/2001	Parker	
		6,325,761 B1	12/2001	Jay	
		6,334,065 B1	12/2001	Al-Ali et al.	
		6,343,224 B1	1/2002	Parker	
		6,349,228 B1 *	2/2002	Kiani	A61B 5/14551 439/909
		6,360,114 B1	3/2002	Diab et al.	
		6,368,283 B1	4/2002	Xu et al.	
		6,371,921 B1	4/2002	Caro et al.	
		6,377,829 B1	4/2002	Al-Ali	
		6,388,240 B2	5/2002	Schulz et al.	
		6,397,091 B2	5/2002	Diab et al.	
		6,430,437 B1	8/2002	Marro	
		6,430,525 B1	8/2002	Weber et al.	
		6,463,311 B1	10/2002	Diab	
		6,470,199 B1	10/2002	Kopotic et al.	
		6,501,975 B2	12/2002	Diab et al.	
		6,505,059 B1	1/2003	Kollias et al.	
		6,515,273 B2	2/2003	Al-Ali	
		6,519,487 B1	2/2003	Parker	
		6,525,386 B1	2/2003	Mills et al.	
		6,526,300 B1	2/2003	Kiani et al.	
		6,541,756 B2	4/2003	Schulz et al.	
		6,542,764 B1	4/2003	Al-Ali et al.	
		6,580,086 B1	6/2003	Schulz et al.	
		6,584,336 B1 *	6/2003	Ali	A61B 5/14551 600/323
		6,595,316 B2	7/2003	Cybulski et al.	
		6,597,932 B2	7/2003	Tian et al.	
		6,597,933 B2	7/2003	Kiani et al.	
		6,606,511 B1	8/2003	Ali et al.	
		6,631,291 B2	10/2003	Viertio-Oja et al.	
		6,632,181 B2	10/2003	Flaherty et al.	
		6,639,668 B1	10/2003	Trepagnier	
		6,640,116 B2	10/2003	Diab	
		6,643,530 B2	11/2003	Diab et al.	
		6,650,917 B2	11/2003	Diab et al.	
		6,654,624 B2	11/2003	Diab et al.	
		6,658,276 B2	12/2003	Kianl et al.	
		6,661,161 B1	12/2003	Lanzo et al.	
		6,671,531 B2	12/2003	Al-Ali et al.	
		6,678,543 B2	1/2004	Diab et al.	
		6,684,090 B2	1/2004	Ali et al.	
		6,684,091 B2	1/2004	Parker	
		6,697,656 B1	2/2004	Al-Ali	
		6,697,657 B1	2/2004	Shehada et al.	
		6,697,658 B2	2/2004	Al-Ali	
		RE38,476 E	3/2004	Diab et al.	
		6,699,194 B1	3/2004	Diab et al.	
		6,714,804 B2	3/2004	Al-Ali et al.	
		RE38,492 E	4/2004	Diab et al.	
		6,721,582 B2	4/2004	Trepagnier et al.	
		6,721,585 B1	4/2004	Parker	
		6,725,075 B2	4/2004	Al-Ali	
		6,728,560 B2	4/2004	Kollias et al.	
		6,735,459 B2	5/2004	Parker	
		6,745,060 B2	6/2004	Diab et al.	
		6,760,607 B2	7/2004	Al-Ali	
		6,768,920 B2 *	7/2004	Lange	A61B 5/0478 600/300
		6,770,028 B1 *	8/2004	Ali	A61B 5/0002 600/300
		5,337,744 A	8/1994	Branigan	
		5,341,805 A	8/1994	Stavridi et al.	
		D353,195 S	12/1994	Savage et al.	
		D353,196 S	12/1994	Savage et al.	
		5,377,676 A	1/1995	Vari et al.	
		D359,546 S	6/1995	Savage et al.	
		5,431,170 A	7/1995	Mathews	
		D361,840 S	8/1995	Savage et al.	
		5,441,528 A *	8/1995	Chang	A61N 1/40 600/26
		D362,063 S	9/1995	Savage et al.	
		5,452,717 A	9/1995	Branigan et al.	
		D363,120 S	10/1995	Savage et al.	
		5,456,252 A	10/1995	Vari et al.	
		5,479,934 A	1/1996	Imran	
		5,482,036 A	1/1996	Diab et al.	
		5,490,505 A *	2/1996	Diab	A61B 5/14551 356/41
		5,494,043 A	2/1996	O'Sullivan et al.	
		5,533,511 A	7/1996	Kaspari et al.	
		5,534,851 A	7/1996	Russek	
		5,544,661 A *	8/1996	Davis	A61B 5/0002 128/904
		5,561,275 A	10/1996	Savage et al.	
		5,562,002 A	10/1996	Lalin	
		5,590,649 A	1/1997	Caro et al.	
		5,602,924 A	2/1997	Durand et al.	
		5,632,272 A	5/1997	Diab et al.	
		5,638,816 A	6/1997	Kiani-Azarbayjany et al.	
		5,638,818 A	6/1997	Diab et al.	
		5,645,440 A	7/1997	Tobler et al.	
		5,685,299 A	11/1997	Diab et al.	
		D393,830 S	4/1998	Tobler et al.	
		5,743,262 A	4/1998	Lepper, Jr. et al.	
		5,758,644 A	6/1998	Diab et al.	
		5,760,910 A	6/1998	Lepper, Jr. et al.	
		5,769,785 A	6/1998	Diab et al.	
		5,782,757 A	7/1998	Diab et al.	
		5,785,659 A	7/1998	Caro et al.	
		5,791,347 A	8/1998	Flaherty et al.	
		5,810,734 A	9/1998	Caro et al.	
		5,823,950 A	10/1998	Diab et al.	
		5,830,131 A	11/1998	Caro et al.	
		5,833,618 A	11/1998	Caro et al.	
		5,860,919 A	1/1999	Kiani-Azarbayjany et al.	
		5,890,929 A	4/1999	Mills et al.	
		5,904,654 A	5/1999	Wohltmann et al.	
		5,919,134 A	7/1999	Diab	
		5,934,925 A	8/1999	Tobler et al.	
		5,940,182 A	8/1999	Lepper, Jr. et al.	
		5,995,855 A *	11/1999	Kiani	A61B 5/14551 600/310
		5,997,343 A	12/1999	Mills et al.	
		6,002,952 A	12/1999	Diab et al.	
		6,011,986 A	1/2000	Diab et al.	
		6,018,682 A *	1/2000	Rise	A61B 5/4094 607/45
		6,027,452 A	2/2000	Flaherty et al.	
		6,036,642 A	3/2000	Diab et al.	
		6,045,509 A	4/2000	Caro et al.	
		6,047,203 A *	4/2000	Sackner	A41D 13/1281 600/301
		6,067,462 A	5/2000	Diab et al.	
		6,081,735 A *	6/2000	Diab	G06K 9/0051 600/336
		6,088,607 A	7/2000	Diab et al.	
		6,110,522 A	8/2000	Lepper, Jr. et al.	
		6,124,597 A	9/2000	Shehada	
		6,128,521 A	10/2000	Marro et al.	
		6,129,675 A	10/2000	Jay	
		6,144,868 A	11/2000	Parker	
		6,151,516 A	11/2000	Kiani-Azarbayjany et al.	
		6,152,754 A	11/2000	Gerhardt et al.	

(56)		References Cited						
		U.S. PATENT DOCUMENTS						
6,771,994	B2	8/2004	Kiani et al.		7,343,186	B2	3/2008	Lamego et al.
6,792,300	B1	9/2004	Diab et al.		D566,282	S	4/2008	Al-Ali et al.
6,813,511	B2	11/2004	Diab et al.		7,355,512	B1	4/2008	Al-Ali
6,816,741	B2	11/2004	Diab		7,356,365	B2	4/2008	Schurman
6,822,564	B2	11/2004	Al-Ali		7,371,981	B2	5/2008	Abdul-Hafiz
6,826,419	B2	11/2004	Diab et al.		7,373,193	B2	5/2008	Al-Ali et al.
6,830,711	B2	12/2004	Mills et al.		7,373,194	B2	5/2008	Weber et al.
6,850,787	B2	2/2005	Weber et al.		7,376,453	B1	5/2008	Diab et al.
6,850,788	B2	2/2005	Al-Ali		7,377,794	B2	5/2008	Al Ali et al.
6,852,083	B2	2/2005	Caro et al.		7,377,899	B2	5/2008	Weber et al.
6,861,639	B2	3/2005	Al-Ali		7,383,070	B2	6/2008	Diab et al.
6,898,452	B2	5/2005	Al-Ali et al.		7,415,297	B2 *	8/2008	Al-Ali A61B 5/14551
6,920,345	B2	7/2005	Al-Ali et al.					340/511
6,931,268	B1	8/2005	Kiani-Azarbayjany et al.		7,428,432	B2 *	9/2008	Ali A61B 5/0002
6,934,570	B2 *	8/2005	Kiani A61B 5/0478					600/323
				600/324				
6,939,305	B2	9/2005	Flaherty et al.		7,438,683	B2	10/2008	Al-Ali et al.
6,943,348	B1	9/2005	Coffin, IV		7,440,787	B2	10/2008	Diab
6,950,687	B2	9/2005	Al-Ali		7,454,240	B2	11/2008	Diab et al.
6,961,598	B2	11/2005	Diab		7,467,002	B2	12/2008	Weber et al.
6,970,792	B1	11/2005	Diab		7,469,157	B2	12/2008	Diab et al.
6,979,812	B2	12/2005	Al-Ali		7,471,969	B2	12/2008	Diab et al.
6,985,764	B2	1/2006	Mason et al.		7,471,971	B2	12/2008	Diab et al.
6,993,371	B2	1/2006	Kiani et al.		7,483,729	B2	1/2009	Al-Ali et al.
6,996,427	B2	2/2006	Ali et al.		7,483,730	B2	1/2009	Diab et al.
6,999,904	B2	2/2006	Weber et al.		7,489,958	B2	2/2009	Diab et al.
7,003,338	B2	2/2006	Weber et al.		7,496,391	B2	2/2009	Diab et al.
7,003,339	B2	2/2006	Diab et al.		7,496,393	B2	2/2009	Diab et al.
7,015,451	B2	3/2006	Dalke et al.		D587,657	S	3/2009	Al-Ali et al.
7,024,233	B2	4/2006	Ali et al.		7,499,741	B2	3/2009	Diab et al.
7,027,849	B2	4/2006	Al-Ali		7,499,835	B2	3/2009	Weber et al.
7,030,749	B2	4/2006	Al-Ali		7,500,950	B2	3/2009	Al-Ali et al.
7,039,449	B2	5/2006	Al-Ali		7,509,154	B2	3/2009	Diab et al.
7,041,060	B2	5/2006	Flaherty et al.		7,509,494	B2	3/2009	Al-Ali
7,044,918	B2	5/2006	Diab		7,510,849	B2	3/2009	Schurman et al.
7,067,893	B2	6/2006	Mills et al.		7,526,328	B2	4/2009	Diab et al.
7,089,927	B2 *	8/2006	John A61B 5/048		7,530,942	B1	5/2009	Diab
				128/200.24	7,530,949	B2 *	5/2009	Al Ali A61B 5/0002
								600/300
7,096,052	B2	8/2006	Mason et al.		7,530,955	B2	5/2009	Diab et al.
7,096,054	B2	8/2006	Abdul-Hafiz et al.		7,563,110	B2	7/2009	Al-Ali et al.
7,132,641	B2	11/2006	Schulz et al.		7,596,398	B2	9/2009	Al-Ali et al.
7,142,901	B2	11/2006	Kiani et al.		7,618,375	B2	11/2009	Flaherty
7,146,211	B2 *	12/2006	Frei A61B 5/04012		D606,659	S	12/2009	Kiani et al.
				607/2	7,647,083	B2	1/2010	Al-Ali et al.
7,149,561	B2	12/2006	Diab		D609,193	S	2/2010	Al-Ali et al.
7,186,966	B2	3/2007	Al-Ali		D614,305	S	4/2010	Al-Ali et al.
7,190,261	B2	3/2007	Al-Ali		RE41,317	E	5/2010	Parker
7,215,984	B2	5/2007	Diab		7,715,919	B2 *	5/2010	Osorio A61N 1/36014
7,215,986	B2	5/2007	Diab					607/45
7,221,971	B2	5/2007	Diab		7,729,733	B2	6/2010	Al-Ali et al.
7,225,006	B2	5/2007	Al-Ali et al.		7,734,320	B2	6/2010	Al-Ali
7,225,007	B2	5/2007	Al-Ali		7,761,127	B2	7/2010	Al-Ali et al.
RE39,672	E	6/2007	Shehada et al.		7,761,128	B2	7/2010	Al-Ali et al.
7,239,905	B2	7/2007	Kiani-Azarbayjany et al.		7,764,982	B2	7/2010	Dalke et al.
7,245,953	B1	7/2007	Parker		D621,516	S	8/2010	Kiani et al.
7,254,429	B2	8/2007	Schurman et al.		7,783,343	B2 *	8/2010	Sarkela A61B 5/048
7,254,431	B2	8/2007	Al-Ali					600/544
7,254,433	B2	8/2007	Diab et al.		7,791,155	B2	9/2010	Diab
7,254,434	B2	8/2007	Schulz et al.		7,801,581	B2	9/2010	Diab
7,272,425	B2	9/2007	Al-Ali		7,811,279	B2 *	10/2010	John A61M 25/0026
7,274,955	B2	9/2007	Kiani et al.					604/890.1
D554,263	S	10/2007	Al-Ali		7,822,452	B2	10/2010	Schurman et al.
7,277,758	B2 *	10/2007	DiLorenzo A61N 1/36082		RE41,912	E	11/2010	Parker
				607/45	7,844,313	B2	11/2010	Kiani et al.
7,280,858	B2	10/2007	Al-Ali et al.		7,844,314	B2	11/2010	Al-Ali
7,289,835	B2	10/2007	Mansfield et al.		7,844,315	B2	11/2010	Al-Ali
7,292,883	B2	11/2007	De Felice et al.		7,865,222	B2	1/2011	Weber et al.
7,295,866	B2	11/2007	Al-Ali		7,873,497	B2	1/2011	Weber et al.
7,299,088	B1 *	11/2007	Thakor A61B 5/048		7,880,606	B2	2/2011	Al-Ali
				600/544	7,880,626	B2	2/2011	Al-Ali et al.
7,328,053	B1	2/2008	Diab et al.		7,891,355	B2	2/2011	Al-Ali et al.
7,332,784	B2	2/2008	Mills et al.		7,894,868	B2	2/2011	Al-Ali et al.
7,340,287	B2	3/2008	Mason et al.		7,899,507	B2	3/2011	Al-Ali et al.
7,341,559	B2	3/2008	Schulz et al.		7,899,518	B2	3/2011	Trepagnier et al.
					7,904,132	B2	3/2011	Weber et al.
					7,909,772	B2	3/2011	Popov et al.
					7,910,875	B2	3/2011	Al-Ali
					7,919,713	B2	4/2011	Al-Ali et al.
					7,937,128	B2	5/2011	Al-Ali

(56)

References Cited

U.S. PATENT DOCUMENTS

7,937,129 B2	5/2011	Mason et al.	8,414,499 B2	4/2013	Al-Ali et al.
7,937,130 B2	5/2011	Diab et al.	8,418,524 B2	4/2013	Al-Ali
7,941,199 B2	5/2011	Kiani	8,423,106 B2	4/2013	Lamego et al.
7,951,086 B2	5/2011	Flaherty et al.	8,428,967 B2	4/2013	Olsen et al.
7,957,780 B2	6/2011	Lamego et al.	8,430,817 B1	4/2013	Al-Ali et al.
7,962,188 B2	6/2011	Kiani et al.	8,437,825 B2	5/2013	Dalvi et al.
7,962,190 B1	6/2011	Diab et al.	8,455,290 B2	6/2013	Siskavich
7,976,472 B2	7/2011	Kiani	8,457,703 B2	6/2013	Al-Ali
7,988,637 B2	8/2011	Diab	8,457,707 B2	6/2013	Kiani
7,990,382 B2	8/2011	Kiani	8,463,349 B2	6/2013	Diab et al.
7,991,446 B2*	8/2011	Ali A61B 5/0002 600/322	8,466,286 B2	6/2013	Bellott et al.
8,000,761 B2	8/2011	Al-Ali	8,471,713 B2	6/2013	Poeze et al.
8,008,088 B2	8/2011	Bellott et al.	8,473,020 B2	6/2013	Kiani et al.
RE42,753 E	9/2011	Kiani-Azarbayjany et al.	8,483,787 B2	7/2013	Al-Ali et al.
8,019,400 B2	9/2011	Diab et al.	8,489,364 B2	7/2013	Weber et al.
8,028,701 B2	10/2011	Al-Ali et al.	8,498,684 B2	7/2013	Weber et al.
8,029,765 B2	10/2011	Bellott et al.	8,504,128 B2	8/2013	Blank et al.
8,036,727 B2	10/2011	Schurman et al.	8,509,867 B2	8/2013	Workman et al.
8,036,728 B2	10/2011	Diab et al.	8,515,509 B2	8/2013	Bruinsma et al.
8,046,040 B2	10/2011	Ali et al.	8,523,781 B2	9/2013	Al-Ali
8,046,041 B2	10/2011	Diab et al.	8,529,301 B2	9/2013	Al-Ali et al.
8,046,042 B2	10/2011	Diab et al.	8,532,727 B2	9/2013	Ali et al.
8,048,040 B2	11/2011	Kiani	8,532,728 B2	9/2013	Diab et al.
8,050,728 B2	11/2011	Al-Ali et al.	D692,145 S	10/2013	Al-Ali et al.
RE43,169 E	2/2012	Parker	8,547,209 B2	10/2013	Kiani et al.
8,118,620 B2	2/2012	Al-Ali et al.	8,548,548 B2	10/2013	Al-Ali
8,126,528 B2	2/2012	Diab et al.	8,548,549 B2	10/2013	Schurman et al.
8,128,572 B2	3/2012	Diab et al.	8,548,550 B2	10/2013	Al-Ali et al.
8,130,105 B2	3/2012	Al-Ali et al.	8,560,032 B2	10/2013	Al-Ali et al.
8,145,287 B2	3/2012	Diab et al.	8,560,034 B1	10/2013	Diab et al.
8,150,487 B2	4/2012	Diab et al.	8,570,167 B2	10/2013	Al-Ali
8,175,672 B2	5/2012	Parker	8,570,503 B2	10/2013	Vo et al.
8,180,420 B2	5/2012	Diab et al.	8,571,617 B2	10/2013	Reichgott et al.
8,182,443 B1*	5/2012	Kiani A61M 16/12 604/131	8,571,618 B1	10/2013	Lamego et al.
8,185,180 B2	5/2012	Diab et al.	8,571,619 B2	10/2013	Al-Ali et al.
8,187,181 B2*	5/2012	Osorio A61B 5/048 128/920	8,577,431 B2	11/2013	Lamego et al.
8,190,223 B2	5/2012	Al-Ali et al.	8,584,345 B2	11/2013	Al-Ali et al.
8,190,227 B2	5/2012	Diab et al.	8,588,880 B2	11/2013	Abdul-Hafiz et al.
8,203,438 B2	6/2012	Kiani et al.	8,600,467 B2	12/2013	Al-Ali et al.
8,203,704 B2	6/2012	Merritt et al.	8,606,342 B2	12/2013	Diab
8,204,566 B2	6/2012	Schurman et al.	8,626,255 B2	1/2014	Al-Ali et al.
8,219,172 B2	7/2012	Schurman et al.	8,630,691 B2	1/2014	Lamego et al.
8,224,411 B2	7/2012	Al-Ali et al.	8,634,889 B2	1/2014	Al-Ali et al.
8,228,181 B2	7/2012	Al-Ali	8,641,631 B2	2/2014	Sierra et al.
8,229,533 B2	7/2012	Diab et al.	8,652,060 B2	2/2014	Al-Ali
8,233,955 B2	7/2012	Al-Ali et al.	8,663,107 B2	3/2014	Kiani
8,244,325 B2	8/2012	Al-Ali et al.	8,666,468 B1	3/2014	Al-Ali
8,255,026 B1	8/2012	Al-Ali	8,667,967 B2	3/2014	Al-Ali et al.
8,255,027 B2	8/2012	Al-Ali et al.	8,670,811 B2	3/2014	O'Reilly
8,255,028 B2	8/2012	Al-Ali et al.	8,670,814 B2	3/2014	Diab et al.
8,260,577 B2	9/2012	Weber et al.	8,676,286 B2	3/2014	Weber et al.
8,265,723 B1	9/2012	McHale et al.	8,682,407 B2	3/2014	Al-Ali
8,274,360 B2	9/2012	Sampath et al.	RE44,823 E	4/2014	Parker
8,301,217 B2	10/2012	Al-Ali et al.	RE44,875 E	4/2014	Kiani et al.
8,306,596 B2	11/2012	Schurman et al.	8,690,799 B2	4/2014	Telfort et al.
8,310,336 B2	11/2012	Muhsin et al.	8,700,112 B2	4/2014	Kiani
8,315,683 B2	11/2012	Al-Ali et al.	8,702,627 B2	4/2014	Telfort et al.
RE43,860 E	12/2012	Parker	8,706,179 B2	4/2014	Parker
8,337,403 B2	12/2012	Al-Ali et al.	8,712,494 B1	4/2014	MacNeish, III et al.
8,346,330 B2	1/2013	Lamego	8,715,206 B2	5/2014	Telfort et al.
8,353,842 B2	1/2013	Al-Ali et al.	8,718,735 B2	5/2014	Lamego et al.
8,355,766 B2	1/2013	MacNeish, III et al.	8,718,737 B2	5/2014	Diab et al.
8,359,080 B2	1/2013	Diab et al.	8,718,738 B2	5/2014	Blank et al.
8,364,223 B2	1/2013	Al-Ali et al.	8,720,249 B2	5/2014	Al-Ali
8,364,226 B2	1/2013	Diab et al.	8,721,541 B2	5/2014	Al-Ali et al.
8,374,665 B2	2/2013	Lamego	8,721,542 B2	5/2014	Al-Ali et al.
8,385,995 B2	2/2013	Al-Ali et al.	8,723,677 B1	5/2014	Kiani
8,385,996 B2	2/2013	Smith et al.	8,740,792 B1	6/2014	Kiani et al.
8,388,353 B2	3/2013	Kiani et al.	8,754,776 B2	6/2014	Poeze et al.
8,399,822 B2	3/2013	Al-Ali	8,755,535 B2	6/2014	Telfort et al.
8,401,602 B2	3/2013	Kiani	8,755,856 B2	6/2014	Diab et al.
8,405,608 B2	3/2013	Al-Ali et al.	8,755,872 B1	6/2014	Marinow
			8,761,850 B2	6/2014	Lamego
			8,764,671 B2	7/2014	Kiani
			8,768,423 B2	7/2014	Shakespeare et al.
			8,771,204 B2	7/2014	Telfort et al.
			2002/0099409 A1*	7/2002	Hui A61G 7/05776 606/201

(56)

References Cited

U.S. PATENT DOCUMENTS

2002/0173729 A1* 11/2002 Viertio-Oja A61B 5/0476
600/544

2004/0015091 A1* 1/2004 Greenwald A61B 5/02125
600/513

2004/0092809 A1* 5/2004 DeCharms G01R 33/4806
600/410

2005/0113744 A1* 5/2005 Donoghue A61F 2/72
604/66

2005/0277819 A1* 12/2005 Kiani A61B 5/0478
600/324

2007/0010755 A1* 1/2007 Sarkela A61B 5/048
600/544

2007/0021673 A1* 1/2007 Arbel A61B 5/02
600/500

2007/0287931 A1* 12/2007 Dilorenzo A61B 5/0476
600/545

2008/0033490 A1* 2/2008 Giftakis A61B 5/0402
607/2

2008/0103375 A1* 5/2008 Kiani A61B 5/0002
600/323

2008/0188760 A1* 8/2008 Al-Ali A61B 5/14551
600/507

2008/0300471 A1* 12/2008 Al-Ali A61B 5/14551
600/301

2008/0317672 A1* 12/2008 Viertio-Oja A61B 5/0476
424/9.2

2009/0069642 A1* 3/2009 Gao A61B 5/02055
600/300

2009/0099627 A1* 4/2009 Molnar A61B 5/04014
607/62

2009/0264789 A1* 10/2009 Molnar A61N 1/36135
600/544

2010/0030089 A1* 2/2010 Hyde G06F 19/3481
600/508

2010/0100036 A1* 4/2010 Leuthardt G06F 19/3481
604/65

2010/0261979 A1* 10/2010 Kiani A61B 5/0002
600/301

2011/0087081 A1* 4/2011 Kiani A61B 5/0002
600/301

2011/0172561 A1* 7/2011 Kiani A61B 7/003
600/586

2011/0208018 A1* 8/2011 Kiani A61B 5/0205
600/301

2011/0245633 A1* 10/2011 Goldberg A61B 5/681
600/301

2015/0359489 A1* 12/2015 Baudenbacher G06F 19/3418
600/300

OTHER PUBLICATIONS

Hager et al. The Perfusion Index Measured by a Pulse Oximeter Indicates Pain Stimuli in Anesthetized Volunteers, ASA Abstract 2003, Anesthesiology 2004; 101: A514.

Lopez-Silva et al. Transmittance Photoplethysmography and Pulse Oximetry with Near Infrared Laser Diodes, IMTC 2004—Instrumentation and Measurement, Technology Conference, May 2004.

Voss and Sleight, Best Practice and Research Clinical Anaesthesiology, vol. 21, No. 3, pp. 313-325, 2007.

* cited by examiner




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5A




FIG. 5B




FIG. 6




FIG. 7A




FIG. 7B




FIG. 7D




FIG. 7C




FIG. 7E




FIG. 8

OPTICAL-BASED PHYSIOLOGICAL MONITORING SYSTEM

CROSS-REFERENCE TO RELATED APPLICATIONS

Any and all applications for which a foreign or domestic priority claim is identified in the Application Data Sheet as filed with the present application are hereby incorporated by reference under 37 CFR 1.57.

This application is a continuation of U.S. patent application Ser. No. 12/885,430, filed Sep. 17, 2010, and titled "Pharmacological Management System," which claims priority benefit under 35 U.S.C. §119(e) to U.S. Provisional Patent Application No. 61/243,161, filed Sep. 17, 2009, and titled "Pharmacological Management System." The entire disclosure of each of the above items is hereby made part of this specification as if set forth fully herein and incorporated by reference for all purposes, for all that it contains.

BACKGROUND

Generation and analysis of an electroencephalogram (EEG) is a widely accepted noninvasive procedure for diagnosing a person's neurological system. For example, an EEG can reflect changes in a brain's cellular function due to insufficient oxygen or drugs, to name a few. An EEG system consists of a bio-potential sensor and corresponding monitor to process, analyze and display an EEG signal and corresponding neurological parameters. A bio-potential sensor responds to the electrical potential difference between at least two well-spaced electrodes, using a separate ground electrode. The biopotential monitor typically displays the EEG waveform and a numerical index that reflects changes in the EEG bandwidth and power.

Generation and analysis of a photoplethysmograph is a widely accepted noninvasive procedure for diagnosing a person's cardiovascular system. For example, a photoplethysmograph can yield the oxygen saturation level of arterial blood, an indicator of a person's oxygen supply. A pulse oximetry system consists of an optical sensor applied to a fleshy tissue site, such as a fingertip, and a corresponding pulse oximetry monitor (pulse oximeter). Using multiple wavelength light emitting diodes and a corresponding detector, the optical sensor measures the light absorption of the pulsatile blood at the tissue site. In particular, the optical sensor is responsive to the instantaneous blood volume as well as the blood constituency. Accordingly, the pulse oximeter typically displays a numerical readout of a person's oxygen saturation and pulse rate along with an audible indication of the person's pulse. The photoplethysmograph waveform may also be displayed.

Conventional pulse oximetry assumes that arterial blood is the only pulsatile blood flow in the measurement site. During patient motion, venous blood also moves, which causes errors in conventional pulse oximetry. Advanced pulse oximetry processes the venous blood signal so as to report true arterial oxygen saturation and pulse rate under conditions of patient movement. Advanced pulse oximetry also functions under conditions of low perfusion (small signal amplitude), intense ambient light (artificial or sunlight) and electrosurgical instrument interference, which are scenarios where conventional pulse oximetry tends to fail.

Advanced pulse oximetry is described in at least U.S. Pat. Nos. 6,770,028; 6,658,276; 6,157,850; 6,002,952; 5,769,785 and 5,758,644, which are assigned to Masimo Corporation ("Masimo") of Irvine, Calif. and are incorporated by refer-

ence herein. Corresponding low noise optical sensors are disclosed in at least U.S. Pat. Nos. 6,985,764; 6,813,511; 6,792,300; 6,256,523; 6,088,607; 5,782,757 and 5,638,818, which are also assigned to Masimo and are also incorporated by reference herein. Advanced pulse oximetry systems including Masimo SET® low noise optical sensors and read through motion pulse oximetry monitors for measuring SpO₂, pulse rate (PR) and perfusion index (PI) are available from Masimo. Optical sensors include any of Masimo LNOP®, LNCS®, SofTouch™ and Blue™ adhesive or reusable sensors. Pulse oximetry monitors include any of Masimo Rad-8®, Rad-5®, Rad®-5v or SatShare® monitors.

Advanced blood parameter measurement systems are described in at least U.S. Pat. No. 7,647,083, filed Mar. 1, 2006, titled *Multiple Wavelength Sensor Equalization*; U.S. Pat. No. 7,729,733, filed Mar. 1, 2006, titled *Configurable Physiological Measurement System*; U.S. Pat. Pub. No. 2006/0211925, filed Mar. 1, 2006, titled *Physiological Parameter Confidence Measure* and U.S. Pat. Pub. No. 2006/0238358, filed Mar. 1, 2006, titled *Noninvasive Multi-Parameter Patient Monitor*, all assigned to Masimo Laboratories, Irvine, Calif. (Masimo Labs) and all incorporated by reference herein. Advanced blood parameter measurement systems include Masimo Rainbow® SET, which provides measurements in addition to SpO₂, such as total hemoglobin (SpHb™), oxygen content (SpOC™) methemoglobin (SpMet®), carboxyhemoglobin (SpCO®) and PVI®. Advanced blood parameter sensors include Masimo Rainbow® adhesive, ReSpisable™ and reusable sensors. Advanced blood parameter monitors include Masimo Radical-7™, Rad-87™ and Rad-57™ monitors, all available from Masimo. Such advanced pulse oximeters, low noise sensors and advanced blood parameter systems have gained rapid acceptance in a wide variety of medical applications, including surgical wards, intensive care and neonatal units, general wards, home care, physical training, and virtually all types of monitoring scenarios.

SUMMARY

Depth of consciousness (DOC) is an important physiological assessment during the administration of anesthesia and analgesia drugs. For example, an overdose of anesthesia risks physical impairment or death. An underdose of anesthesia risks "surgical awareness." A DOC index is typically derived by an EEG sensor measurement of electrical activity in the cerebral cortex. Advantageously, the measurement of various cardio-vascular system and respiratory system responses can substitute for or supplement typical central nervous system measures of consciousness, providing improved resolution and accuracy. For example, cardiovascular system and respiratory system parameters responsive to consciousness may include perfusion index (PI), plethysmograph variability index (PVI), heart rate (HR), blood pressure (BP) and respiration rate (RR), to name a few.

Level of pain (LOP) is also an important physiological assessment during anesthesia and analgesia. A LOP index is an advantageous quantization of pain that allows proper dosing of administered drugs. Advantageously, a LOP index may also be derived from various cardiovascular system and respiratory system parameters, such as those cited above.

Although dissimilar physiological phenomena, there is an important relationship between consciousness and pain for anesthesia and analgesia applications. During anesthesia, it is desirable to ensure that pain is eliminated during apparent unconsciousness. During analgesia, it is desirable for pain to

be diminished or eliminated without impinging on consciousness. Accordingly, parameters useful in conjunction with consciousness assessment may be useful in conjunction with pain assessment and vice-a-versa.

A pharmacological management system advantageously provides sensors and processors to measure and analyze both DOC and LOP. Accordingly, a pharmacological management system advantageously senses and analyzes both consciousness and pain related physiological signals so as to generate multidimensional parameters or indexes indicative of both physiological processes.

One aspect of a pharmacological management system comprises sensors, a pharmacological status monitor and a drug administrator. The sensors attach to the patient so as to generate corresponding sensor signals. The pharmacological status monitor is responsive to the sensor signals so as to generate an output indicative of the drug-induced effects of the pharmacological agent on the patient. Further, the monitor output is fed-back to the drug administrator so as to regulate administration of the agent for a desired effect.

In various embodiments, the monitor comprises a hematological processor responsive to an optical sensor signal and a neurological processor responsive to a bio-potential sensor. The hematological processor has a photoplethysmograph input and provides a level of pain output to the pharmacological status monitor. The neurological processor has an EEG input and provides a depth of consciousness output to the pharmacological status monitor. The pharmacological status monitor generates a control output to a drug-infusion pump. The level of pain output is a perfusion index. The pharmacological status monitor generates a combined index related to both depth of consciousness and level of pain.

Another aspect of a pharmacological management system is inputting sensor signals derived from a patient and calculating physiological parameters accordingly. The sensor signals provide measurements of physiological systems. Physiological parameters are calculated from the sensor signals. The parameters are operated on to generate monitor outputs, which are indicative of levels of both consciousness and pain.

In various embodiments, a first sensor signal is utilized to generate a consciousness index and a second sensor signal is utilized to generate a perfusion index. Cues are displayed to indicate a patient with a stable or unstable physiological condition. Outputs control drug-infusion equipment or medical gas ventilation equipment. Patient wellness is diagnosed.

A further aspect of a pharmacological management system measures physiological parameters derived from at least some of a patient's central nervous system, respiratory system and cardio-vascular system so as to assess level of pain and depth of consciousness during the administration of anesthetic and analgesic agents. The pharmacological management system comprises sensors in communications with a patient so as to generate sensor signals and a monitor front-end in communications with the sensor signals so as to generate digitized sensor signals. A signal processor is in communications with the front-end so as to generate physiological parameters. The signal processor derives an electrical-based depth of consciousness (DOC) indicator from an electrical one of the sensors in communications with the patient's central nervous system and a pleth-based level of pain (LOP) indicator from an optical one of the sensors in communications with the patient's cardio-vascular system.

An instrument manager generates a monitor output in response to a combination of the DOC indicator and the LOP indicator.

In various embodiments, a drug administrator administers a pharmacological agent to the patient and is responsive to the monitor output. The LOP indicator is responsive to a perfusion index (PI) parameter or a plethysmograph variability index (PVI) parameter. The monitor output comprises an electronic signal to the drug administrator that affects the dose of pharmacological agent. The monitor output also comprises a combined display of LOP and DOC.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a general block diagram of pharmacological management system;

FIG. 2 is a block diagram of a pharmacological management system embodiment responsive to electrical and optical sensors so as to measure consciousness and pain;

FIG. 3 illustrates a pharmacological management system configured for anesthesia applications;

FIG. 4 illustrates a pharmacological management system configured for analgesia applications;

FIGS. 5A-B are illustrations of combination sensor embodiments for measuring both consciousness and pain;

FIG. 6 is a detailed block diagram of a pharmacological management system embodiment;

FIGS. 7A-E are illustrations of a pharmacological status monitor embodiment responsive to various sensors; and

FIG. 8 is an illustration of a multi-sensor embodiment for measuring level of pain and depth of consciousness.

DETAILED DESCRIPTION

FIG. 1 generally illustrates a pharmacological management system 100 having a drug administrator 110 that provides a pharmacological agent 114 to a patient 10 and a pharmacological status monitor 120 responsive to corresponding drug-induced effects 20. Pharmacological agents 114 may be, as examples, anesthesia or analgesia drugs. For anesthesia applications, the desired effect 20 may be general anesthesia or various levels of sedation. The drug administrator 110 may vary from a healthcare provider manually administering drugs to an automatic or semi-automatic machine such as a drug infusion device or medical gas inhalation device. The drug administrator may be responsive to external controls 112, such as manual inputs or electronic signals.

As shown in FIG. 1, drug-induced effects 20 in the patient 10 may include hypnosis 21, analgesia 23, amnesia 25, paralysis 27 and reflex suppression 29. Hypnosis 21 produces unconsciousness; analgesia 23 blocks the conscious sensation of pain; amnesia 25 prevents memory formation; paralysis 27 prevents unwanted movement or muscle tone; and reflex suppression 29 prevents exaggerated autonomic reflexes. For general anesthesia, some or all of these drug-induced effects 20 may be the goal. For low-level sedation, the goal may be to achieve some effects 20 while suppressing others. For pain reduction, analgesia 23 is the goal along with minimization of other drug-induced effects 20.

Also shown in FIG. 1, the pharmacological management system 100 advantageously assists healthcare providers to achieve the above-stated goals, among others. Sensors (not shown) attached to the patient 10 provide biological signals 122 to the pharmacological status monitor 120. The monitor 120 processes these signals 122 and generates outputs 124 indicative of the effects 20 of administered pharmacological

agents 114. The outputs 124 may be displays, alarms, controls or indicators, for example. The outputs 124 may also provide manual or automatic feedback 126 to the drug administrator 110 so as to regulate administration of the agent 114 for the desired effects 20.

FIG. 2 illustrates a pharmacological management system 200 having sensors 201 in communications with a patient 10. The sensors 201 generate sensor waveforms 202 to corresponding monitors 203. The monitors 203 process the waveforms 202 so as to calculate parameters that alone or in combination are indicative of the pharmacological status of the patient 10. In one embodiment, sensors 201 include an electrical (biopotential) sensor 210 placed proximate the head so as to generate an EEG waveform 212 and an optical sensor 220 placed on a fleshy tissue site so as to generate a photoplethysmograph 214.

A neurological monitor 230 processes the EEG waveform 212 to generate a first parameter 232 related to depth of consciousness (DOC). In an embodiment, the first parameter 232 is a dimensionless index that reflects the level of activity of the cerebral cortex. In a particular embodiment, the first parameter 232 is a Bispectral Index™ (BIS) proprietary to Aspect Medical Systems, Inc., Norwood, Mass. (“Aspect”), and the neurological processor 230 is a BIS module also proprietary to Aspect. In another particular embodiment, the first parameter 232 is a Patient State Index™ (PSI) proprietary to Hospira, Inc., Lake Forest, Ill. (“Hospira”), and the neurological processor 230 is a SEDLine monitor or module, also proprietary to Hospira.

A hematological monitor 240 processes the photoplethysmograph (pleth) waveform 214 to generate at least one second parameter 242. In an embodiment, the second parameter is a level of pain (LOP) index. In an embodiment, the second parameter is a pleth-based DOC index providing improved resolution and accuracy in determining DOC compared to only an EEG-based DOC index. In an embodiment, the second parameter 242 is a Perfusion Index (PI) or a Plethysmograph Variability Index (PVI) proprietary to Masimo Corporation, Irvine, Calif. (“Masimo”) or both, and the hematological processor 240 is any of various monitors or modules available from Masimo, such as described above. PI may change dramatically in response to sympathetic changes in vasoconstriction or vasodilation of peripheral vessels reflective of consciousness or pain. PI comprises a relative indication of pulse strength at a monitoring site. For example, PI may be defined as the ratio of a pleth AC value to its DC value, or the percentage of pulsatile signal to non-pulsatile signal. PVI is described in U.S. patent application Ser. No. 11/952,940 filed Dec. 7, 2007 titled *Plethysmograph Variability Index*, assigned to Masimo and incorporated by reference herein.

As shown in FIG. 2, in an embodiment the electrical sensor 210 is any of various EEG sensors having multiple biopotential electrodes for placement across various head sites for detection of electrical signals originating in the brain. In an embodiment, the optical sensor 220 is any of various blood parameter sensors having LED emitters and at least one photodiode detector for placement at various fleshy tissue sites for detection of pulsatile blood flow and in particular the measurement of optical properties thereof, such as absorption, reflection, transmission and transmittance to name a few. In an embodiment, the optical sensor 220 is any of various optical sensors available from Masimo, such as described above.

Further shown in FIG. 2, in an embodiment, and optical sensor may comprise a combination or multi-sensor 250 that provides both EEG and photoplethysmograph waveforms,

such as described with respect to FIGS. 5 and 8, below. In an embodiment, the hematological and neurological monitors may comprise a combination or multi-parameter monitor 260 having hematological and neurological processing plug-ins, modules or similar technology, such as described with respect to FIGS. 6 and 7, below.

FIG. 3 illustrates a pharmacological management system 300 configured for anesthesia applications having a sensor 301 attached to a patient 10, a pharmacological status monitor 303 and a sensor cable 302 providing sensor signal communications between the sensor 301 and the monitor 303. In an embodiment, the sensor 301 provides multiple physiological signals to the monitor 303, which derives at least two different measures of consciousness or at least a measurement of consciousness and a measurement of pain. In an embodiment, these physiological signals are EEG and photoplethysmograph signals. In an embodiment, the monitor 303 calculates both a DOC index and PI from the EEG and plethysmograph signals and displays these parameters on the monitor display 305 accordingly.

As shown in FIG. 3, in a mixed display embodiment 310 a DOC parameter is displayed numerically adjacent a LOP parameter displayed as a color. For example, the DOC parameter may be an index, such as BIS, displayed as a dimensionless number. The LOP parameter may be, for example, PI, displayed as a green, yellow or red indicator depending on a preset range of high, medium and low PI values. The low PI value range being set so as to indicate the occurrence of significant vasoconstriction in response to pain or measurable vasodilation in response to increasing depth of consciousness. In a numerical display embodiment 320, DOC and LOP are displayed as proximately located numerical readouts, such as a DOC index and a perfusion index (PI). In a graphical display embodiment 330, DOC and LOP are separately indicated as trends, such as a DOC index trend and a PI trend. The monitor may also calculate a combined index related to consciousness or pain or both. Other individual or combined parameter displays include any of various readouts, graphs, charts or indicators in any of various single or multiple colors. The above monitoring and display embodiments advantageously assist an anesthesiologist or other administrator of drugs to titrate anesthesia based upon either multiple indicators of DOC or on indicators of DOC and LOP. This dual monitoring of pain and consciousness during administration of anesthesia drugs advantageously increases monitor responsivity to under or over dosing of anesthesia.

FIG. 4 illustrates a pharmacological management system 400 configured for analgesia applications, such as patient controlled analgesia (PCA). In particular, the pharmacological management system 400 has a sensor 401 attached to a patient 10, a pharmacological status monitor 403 and a sensor cable 402 providing sensor signal communications between the sensor 401 and the monitor 403. Further, the monitor 403 generates control signals via a control cable 407 to the drug-infusion pump 420. The drug-infusion pump 420 administers drugs to the patient 10 via a tube 422 and an IV 424. A patient-actuated controller (not shown) generates drug administration requests to the drug-infusion pump 420 via cable or wireless communications. In this manner, the pump 420 responds to patient perceived pain levels. In particular, the patient 10 actuates the controller, such as via a button press, so as to signal the drug-infusion pump 420 to administer a measured analgesia dose. The pump 420 enables or pauses patient-controlled dosing according to monitor 403 signals transmitted via the control cable 407. These control signals are responsive to monitor calculated

DOC and LOP related parameters. Further, these parameters are displayed on a monitor screen **405**, such as described with respect to FIG. **3**, above.

The sensor **401** provides physiological signals to the monitor **403** related to depth of consciousness (DOC) or level of pain (LOP). In an embodiment, these physiological signals are EEG and photoplethysmograph signals. The monitor **403** calculates DOC, LOP or a combination consciousness and pain parameters from the EEG and plethysmograph signals and processes those parameters to generate control outputs **407** to the drug-infusion pump **420**. In this manner, the administration of analgesia is controlled not only according to the patient's perceived pain level, but also according to a physiologically indicated pain level and to avoid consciousness impairment. In a particular embodiment, LOP is indicated by a perfusion index (PI), as described above, and PCA is paused or enabled according to a rising or falling PI, respectively, or according to a DOC index, or both.

FIGS. **5A-B** illustrate combination sensors, which provide inputs to a pharmacological status monitor having both hematological and neurological signal processors, such as described with respect to FIG. **2**, above. FIG. **5A** illustrates a combination sensor **500** applied to the forehead and temple areas of a person. The sensor **500** includes an electrical or more specifically a biopotential sensor **510** and an optical sensor **520**. A patient cable **530** connects the sensor to one or more monitoring devices (not shown), such as described with respect to FIGS. **7A-E**, below. The biopotential sensor **510** may be an EEG sensor for depth of consciousness monitoring, as described above. The optical sensor **520** may be a pulse oximetry reflectance sensor for consciousness or pain monitoring via perfusion index (PI) or other blood parameter, also as described above. The patient cable **530** may connect near the person's temple, as shown, or as an alternative near the person's forehead. The biopotential sensor **510** and optical sensor **520** may share a common connector **540** or each sensor may have a dedicated patient cable connector. Combination EEG and pulse oximetry sensors are described in U.S. Pat. No. 6,934,570, issued Aug. 23, 2005, titled *Physiological Sensor Combination* and incorporated by reference herein.

FIG. **5B** illustrates a combination sensor **501** applied to the forehead, temple and ear concha areas of a person. In one embodiment, the sensor **501** includes a biopotential sensor **511**, an optical sensor **521** and a cable **531** that connects the sensor **501** to one or more monitoring devices (not shown). The biopotential sensor **511** may be an EEG sensor for depth of consciousness monitoring, as described above. The optical sensor **521** may be a pulse oximetry transmissive sensor for level of pain monitoring via perfusion index (PI) or other blood parameter, also as described above. In a particular embodiment, the optical sensor **521** is a "Y"-clip ear sensor that flexes so as to slide over the ear periphery and onto either side of the concha. An emitter and detector located at opposite clip ends can then transmit multiple wavelength light into the concha tissue and detect that light after attenuation by pulsatile blood flow within the concha tissue. Optical ear sensors are described in U.S. Provisional Patent App. No. 61/152,964, filed Feb. 16, 2009, titled *Ear Sensor* and incorporated by reference herein.

FIG. **6** illustrates a pharmacological management system **600** embodiment having multiple sensors **610** in communication with a pharmacological status monitor **630**. The sensors **610** are responsive to various physiological systems **601** so as to generate various sensor signals **603**. A pharmacological status monitor **630** derives physiological

parameters **605** from the sensor signals **603** and operates on the parameters **605** to generate monitor outputs **609**. The measured physiological systems **601** include one or more of the central nervous system, including the brain; the respiratory system, including the lungs; and the cardio-vascular system, including the heart and arteries. The sensors **610** may include electrical sensors **612**, **616**, such as bio-potential sensors that generate EEG **622** and ECG **626** signals in response to brain or heart activity, respectively. The sensors **610** may also include mechanical, acoustical, temperature or humidity sensors **614**, to name a few, that directly or indirectly measure the inspired or expired air flow **624** from the lungs. Sensors **610** include mechanical sensors **618** that measure arterial blood pressure **628**. Sensors **610** further include optical sensors **619** that measure arterial blood flow or volume **629**, according to instantaneous light absorption.

Also shown in FIG. **6**, parameters **605** are any derived measurements indicative of consciousness or pain or both. Parameters **605** may include a consciousness index **652** derived from an EEG signal **622**, such as described with respect to FIG. **2**, above. Parameters **605** may also include a perfusion index (PI) **659** indicative of pain and derived from a photoplethysmograph signal **629**, also described with respect to FIG. **2**, above. Other pain indicative parameters may include respiration rate (RR) **654** derived from a respiratory air flow signal **624**; heart rate (HR) **656**, **658**, **659** derived from an ECG **626**, cuff plethysmograph **628** or photoplethysmograph **629**; and blood pressure (BP) **658** derived from a pressure plethysmograph **628**.

In addition, FIG. **6** shows outputs **609** including displays **662**, alarms **664**, controls **666** and diagnostics **668**. Alarms **664** may be, for example, audible or visual alerts warning of critical conditions that need immediate attention. Controls **666** may be any of various electrical or electronic, wired or wireless or mechanical outputs, to name a few, capable of interfacing with and affecting another device. As examples, controls **666** may interface with drug-infusion equipment or medical gas ventilation equipment, as described above. Diagnostics, including wellness indices, may be audible or visual cues indicating a patient with a stable or unstable physiological condition. Visual cues may be any of various digital readouts, bar graphs, trend graphs, color indicators and the like. Audible cues may be any of various sounds or tones, whether intermittent or continuous or constant or varying in volume.

As shown in FIG. **6**, the monitor **630** has a sensor front end **640**, one or more digital signal processors (DSP) **650** and one or more instrument managers **660**. In an embodiment, the sensor front end **640** may have one or more of various preamps, signal conditioning and analog-to-digital conversion (ADC) that amplify, filter and digitize the sensor signals **603** so as to output digital data channels **642** to a DSP **650**. In an embodiment, the DSP **650** comprises a processing device, such as one based on the Super Harvard ARCHitecture ("SHARC") commercially available from Analog Devices or any other of a wide variety of data and/or signal processors capable of executing programs for determining physiological parameters from input data. In particular, the DSP **650** includes program instructions capable of receiving multiple channels of data **642** from the sensor front end **640**, each channel of which relates to one or more sensor signals **603**.

Also shown in FIG. **6**, the instrument manager **660** may comprise one or more microcontrollers controlling system management, including, for example, translation and communications of calculated parameter data **605** to various outputs **609**. The instrument manager **660** may also act as a

watchdog circuit by, for example, monitoring and controlling the activity of the DSP 650.

FIG. 7A-E illustrate a pharmacological status monitor 700 embodiment capable of inputting signals from a wide range of sensors and of deriving a wide range of physiological parameters therefrom including DOC and LOP parameters, such as BIS and PI described with respect to FIG. 2, above, and others described with respect to FIG. 6, above. The pharmacological status monitor 700 has a docking station 710 including a display 712, a removable shuttle 720, a removable handheld 730 and a combination of plug-in modules 740. The docking station 710 has a shuttle port 714 that allows the shuttle station 720 to dock. The shuttle station 720 has a handheld port 732 that allows the handheld monitor 730 to dock. Accordingly, the modular patient monitor 700 has three-in-one functionality including a handheld 730, a handheld 730 docked into a shuttle station 720 as a handheld/shuttle combination and a handheld/shuttle docked into a docking station 710. When docked, the three modules of handheld 730, shuttle 720 and docking station 710 function as one unit. The handheld 730 docked into the shuttle module 720 functions independently of the docking station 710 and expands the handheld parameter capability to the ability to measure all parameters available to the shuttle 720. The docking station 710, in turn, provides the shuttle 720 or handheld/shuttle combination with a large color display 712 and trim knob control 714 in addition to a power supply/communications module 750 having ports for wireless and hardwired communications, Internet access and printers. In an embodiment, the handheld monitor 730 incorporates blood parameter measurement technologies including SpO₂, PI, HbCO, HbMet, and Hbt, and the shuttle station 720 incorporates non-blood parameters, such as intelligent cuff inflation (101) for blood pressure measurements, acoustic respiration rate (ARR), ECG and EEG to name a few. A multi-parameter monitor is described in U.S. patent Ser. No. 11/903,746, filed Sep. 24, 2007, titled *Modular Patient Monitor* and incorporated by reference herein.

FIG. 8 illustrates an integrated multi-sensor 800 advantageously configured to provide multiple physiological parameter measurements to a pharmacological status monitor 700 (FIGS. 7A-E) via a single connector and interconnected patient cable (not shown). This eliminates the difficulties of a large number of cables and cumbersome connectors when multiple sensors are placed on various areas of a person. In particular, the multi-sensor 800 has a connector 810 in communications with a trunk 820, which fans out to multiple branches 830, each of which terminates in a sensor 840, 850, 860, 870, 880. In an embodiment, the multi-sensor allows measurement of perfusion index (PI) via a pulse oximetry sensor 880 placed on a finger; skin temperature via a thermistor 870 located under an arm; heart rate (HR) via an ECG sensor 860 placed on the chest area; respiration rate (RR) via an acoustic sensor 850 located on the neck to detect airway sounds; and a consciousness index via an EEG sensor 840 placed on the head area.

In other embodiments, other multiple parameter sensors provide sensor inputs to a pharmacological status monitor. A sensor providing both optical and acoustic inputs for blood parameters and acoustic parameters, such as discussed above, in addition to cerebral oximetry, oxygen supply and metabolism among other parameters is described in U.S. Provisional Patent App. No. 61/350,673 titled *Opticoustic Sensor* filed Jun. 2, 2010, assigned to Masimo and incorporated by reference herein. In particular, the cerebral param-

eters measured by the opticoustic sensor disclosed therein may provide further indications of LOP and DOC.

A pharmacological management system has been disclosed in detail in connection with various embodiments. These embodiments are disclosed by way of examples only and are not to limit the scope of the claims that follow. One of ordinary skill in the art will appreciate many variations and modifications.

What is claimed is:

1. A physiological monitoring system comprising:
 - a non-invasive optical sensor comprising:
 - an emitter configured to emit light into a tissue site of a living patient; and
 - a detector configured to detect the emitted light after attenuation by the tissue site and output a first sensor signal responsive to the detected light;
 - one or more bio-potential sensors configured to be attached to the patient and configured to output at least a second sensor signal and a third sensor signal;
 - an additional sensor configured to be attached to the patient and configured to output at least a fourth sensor signal; and
 - a processor configured to:
 - determine, based on the first sensor signal, a first physiological parameter indicative of a level of pain of the patient, wherein the first physiological parameter comprises a perfusion index;
 - determine, based on the second sensor signal, a second physiological parameter indicative of the level of pain of the patient, wherein the second physiological parameter comprises an ECG;
 - determine, based on the third sensor signal, a third physiological parameter indicative of a depth of consciousness of the patient, wherein the third physiological parameter comprises an EEG;
 - determine, based on at least one of the first sensor signal, the second sensor signal, the third sensor signal, or the fourth sensor signal, a plurality of additional physiological parameters indicative of at least one of the level of pain of the patient or the depth of consciousness of the patient, wherein the plurality of additional physiological parameters include at least one of a respiration rate, a respiratory air flow, a heart rate, or a blood pressure; and
 - determine, based on the first physiological parameter, the second physiological parameter, the third physiological parameter, and the plurality of additional physiological parameters, a combined index indicative of both the level of pain and the depth of consciousness of the patient.
2. The physiological monitoring system of claim 1, wherein the processor is further configured to determine, based on the first physiological parameter and the second physiological parameter, a combined indication of the level of pain of the patient.
3. The physiological monitoring system of claim 1, wherein the processor is further configured to determine, based on the first physiological parameter, the second physiological parameter, and the third physiological parameter, a combined indication of both the level of pain and the depth of consciousness of the patient.
4. The physiological monitoring system of claim 1 further comprising:
 - a monitor comprising the processor,
 - wherein the non-invasive optical sensor, the one or more bio-potential sensors, and the additional sensor are in communication with the monitor via a single cable.

5. The physiological monitoring system of claim 1 further comprising:

a drug administration device configured to provide a pharmacological agent to the patient,

wherein the processor is further configured to: 5

output feedback to the drug administration device so as to regulate administration of the pharmacological agent for a desired effect.

6. The physiological monitoring system of claim 1, wherein the processor is further configured to provide a control output to at least one of drug-infusion equipment or medical gas ventilation equipment based at least in part on the combined index indicative of both the level of pain and the depth of consciousness of the patient. 10

7. The physiological monitoring system of claim 1, wherein the processor is further configured to generate a displayable output including a visual indication of the combined index indicative of both the level of pain and the depth of consciousness of the patient. 15

8. The physiological monitoring system of claim 7, wherein the visual indication comprises at least one of a number, a color, or a graph. 20

* * * * *

专利名称(译)	基于光学的生理监测系统		
公开(公告)号	US9517024	公开(公告)日	2016-12-13
申请号	US14/479083	申请日	2014-09-05
[标]申请(专利权)人(译)	梅西莫股份有限公司		
申请(专利权)人(译)	Masimo公司		
当前申请(专利权)人(译)	Masimo公司		
[标]发明人	KIANI MASSI JOE E OREILLY MICHAEL		
发明人	KIANI, MASSI JOE E. O'REILLY, MICHAEL		
IPC分类号	A61B5/1455 A61B5/0402 A61B5/0205 A61B5/00 A61B5/0476		
CPC分类号	A61B5/1455 A61B5/0205 A61B5/0402 A61B5/0476 A61B5/4821 A61B5/021 A61B5/024 A61B5/0816 A61B5/087 A61B5/4839 A61B5/7278 A61B5/7282 A61B5/743		
代理机构(译)	KNOBBE , MARTENS , 奥尔森 & BEAR LLP		
优先权	61/243161 2009-09-17 US		
其他公开文献	US20140378784A1		
外部链接	Espacenet USPTO		

摘要(译)

公开了一种非侵入性的基于光学的生理监测系统。在一个实施例中，非侵入性的基于光学的生理监测系统包括配置成将光发射到活的患者的组织部位中的发射器;检测器，其被配置为检测在被所述组织部位衰减之后的发射光，并响应于检测到的光输出传感器信号;以及处理器，其被配置为基于所述传感器信号确定指示所述患者的疼痛水平的第一生理参数。

